BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 16400838)

  • 1. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 2. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
    Phillips JT
    Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 5. Is natalizumab overshooting its rebound?
    Fox RJ; Kappos L
    Neurology; 2008 Mar; 70(13 Pt 2):1073-4. PubMed ID: 18362270
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Markovic-Plese S; Jewells V; Speer D
    Neurology; 2009 Jun; 72(22):1965; author reply 1965-6. PubMed ID: 19487658
    [No Abstract]   [Full Text] [Related]  

  • 8. Beta interferons for multiple sclerosis.
    Med Lett Drugs Ther; 2002 Oct; 44(1141):88-9. PubMed ID: 12381969
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R; Stürzebecher CS; Kapp JF
    Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
    [No Abstract]   [Full Text] [Related]  

  • 10. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 11. Control of multiple sclerosis relapses with immunomodulating agents.
    Johnson KP
    J Neurol Sci; 2007 May; 256 Suppl 1():S23-8. PubMed ID: 17350652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.
    Pohl D; Rostasy K; Gärtner J; Hanefeld F
    Neurology; 2005 Mar; 64(5):888-90. PubMed ID: 15753430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
    [No Abstract]   [Full Text] [Related]  

  • 16. Seeing injectable MS therapies differently: they are more similar than different.
    Fox RJ; Arnold DL
    Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
    Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
    Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta in multiple sclerosis: how much BENEFIT?
    Pittock SJ
    Lancet; 2007 Aug; 370(9585):363-4. PubMed ID: 17678997
    [No Abstract]   [Full Text] [Related]  

  • 19. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta: the current position.
    Boothman BR
    Br J Hosp Med; 1997 Mar 19-Apr 1; 57(6):277-80. PubMed ID: 9196574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.